Bangladesh J Pharmacol. 2015; 10: 106-114
Available Online: 15 February 2015; DOI: 10.3329/bjp.v10i1.21214
Extract of Brassica rapa suppresses ovalbumin-induced asthma by down-regulating NF-κB and p38 MAPK activity
Yun-Lei Dai1, Gui-Lian Shao2 and Fang Wang3
1Department of Pediatrics, the First Affiliated Hospital of Henan University of TCM, Zhengzhou 450 000, China; 2Department of Pediatrics, Weihai Meternal and Child Health Hospital, Weihai 264 200, China; 3Department of Pediatrics, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou 450 007, China.
Asthma is one of the most common chronic inflammatory diseases characterized by airway infiltration of inflammatory cells inducing hyper-responsiveness. Due to the inefficacy of currently used drugs to definitely cure asthma, there is an insistent need for identification of novel therapies. In the present research, efficiency of Brassica rapa extract in asthma induced mouse model was investigated. Asthma was induced in mice by ovalbumin induction. The extract (125-500 mg/kg) effectively reduced ovalbumin-specific IgE in serum and levels of interleukins (IL): IL-4, IL-5 and IL-13 in bronchoalveolar lavage fluid (BALF). B. rapa extract inhibited inflammatory cell infiltration in BALF and also improved lung compliance and airway resistance. The extract caused marked reduction in the expression levels of phosphorylated ERK, p38, IκB-α and NF-κB, however dose-dependent activation of JNK was observed. The extract of B. rapa thus was effective in suppressing ovalbumin-induced asthma.
Asthma is one of the most common chronic inflammatory diseases, characterized by lung eosinophilia, mucus hypersecretion, and airway hyperresponsiveness (AHR) (Elias et al., 2003; Janson, 2010). The incidence of asthma is increasing at an alarming rate. It is estimated that about 300 million people suffer from asthma, and 250,000 asthma-related deaths occur each year.
Asthma progression is associated with the expression of a broad array of inflammatory proteins. Studies have demonstrated that many of these responses are contributed by T-helper2 (Th2) cells (Busse and Lemanske, 2001; Herrick and Bottomly, 2003). IL-4, IL-5 and IL-13 cytokines secreted from Th2 cells are crucial in allergic airway inflammation (Leigh et al., 2004). NF-κB is also involved in the production of Th2 cytokines and in the recruitment of inflammatory cells (Choi et al., 2004; Kang et al., 2009). Mitogen-activated protein (MAP) p38 kinase has been reported in the activation of various immune cells (Griswold and Young, 1996; Chang et al., 2001). Thus, inhibitors of these inflammatory mediators could be considered as anti-inflammatory drug candidates in asthma (Chio and Park, 2012).
Currently, corticosteroids are considered to be most effective for reducing the symptoms of asthma; how-ever, they do not cure or alter the progression of the disease and also have been reported of systemic and local adverse effects (Walsh, 2005; Shahzad et al., 2009; Hocaoglu et al., 2011). The chronic nature of asthma and inefficacy of the currently used drugs has caused to explore for new therapies (Li, 2009). Complementary or alternative medicine (CAM) approaches are being increasingly used (Li and Brown, 2009). Brassicaceae vegetables consumed widely have beneficial effects due to their bioactive compounds with antioxidant capacity, as vitamins (Wu et al., 2004), phenolics and flavonoids (Powers et al., 2004; Podsedek, 2007). In the present study, the efficacy of Brassica vegetable, Brassica rapa chinensis on ovalbumin induced asthma was investigated.
Reagents and antibodies: The IL-4, IL-5 and IL-13 ELISA kits were purchased from BioLegend, Inc. Camino Santa Fe, Suite E San Diego, CA, USA. All the antibodies used in the study were procured from Cell Signaling Technology Inc, Beverly, MA, USA. Ovalbumin (OVA) was obtained from Sigma-Aldrich, St.Loius MO, USA. All other chemicals and reagents were purchased from Sigma-Aldrich, St.Loius MO, USA unless otherwise are mentioned.
Preparation of B. rapa extract (BRCE): B. rapa was purchased from local grocery mart and were shade dried and finely powdered. A quantity of 100 g of the fine powder was extracted with boiling water for 4 hours and filtered. The residue was extracted again and the supernatants were pooled, condensed and lyophilised for storage at -4°C until use.
Animals: Female BALB/c mice (18-20 g) were obtained from the Centre of Experimental Animals of Baiqiuen Medical College of Jilin University (Jilin, China). All animals were housed in a room under controlled environment (25 ± 1°C, 40-60% humidity) and supplied with water and food provided ad libitum. The mice were acclimatized to in house conditions for a week prior experimentation. All animal experiments were performed in accordance with the guide for the Care and Use of Laboratory Animals published by the US National Institute of Health.
Ovalbumin sensitization and challenge: Mice (BALB/c) were sensitized with OVA as described by Oh et al. (2002) with some modifications. Briefly, OVA (500 µg/mL) in PBS was mixed with an equal volume of 10% (w/v) aqueous aluminum potassium sulphate (alum) and incubated at room temperature for 1 hour after adjusting the pH to 6.5 with 10 N NaOH. Following centrifugation at 750 g for 5 min, the OVA/alum pellet was resuspended at its original volume in distilled water. The mice received 100 µg OVA (0.2 mL of 500 µg/mL solution in normal saline) intra peritonially (i.p) complexed with alum on the first day, and were challenged intranasally (i.n.) on days 8, 15, 18, and 21, as described by Oh et al. (2002). Mice were prepared for challenge by anesthetizing with an i.p injection of 0.2 mL of a mixture of ketamine (0.44 mg/mL) and xylazine (6.3 mg/mL) in normal saline, and were placed on a board in the supine position. Mice received 250 µg OVA (100 µL of a 2.5 mg/mL solution) on day 8 and on days 15, 18, and 21 and were challenged with 125 µg OVA (50 µL of 2.5 mg/mL solution). The control mice received no OVA injections. The treatment group animals were given B. rapa extract (125, 250 and 500 mg/kg; orally) every day from day 1 to day 21. On the days of OVA administration, the mice received B. rapa extract an hour before injections. DEX (2 mg/kg) was injected as i.p as a positive control on the days of OVA injection an hour prior.
OVA-specific IgE: At 24 hours following the last OVA challenge, blood was collected and centrifuged at 3000 rpm for 10 min at 4°C and the serum was stored at -80°C for measurement of IgE. OVA-specific serum IgE levels were determined by enzyme linked immunosorbent absorbent assay (ELISA). Brieflly, microplate wells were coated with 1% OVA in coating buffer (0.05 M sodium carbonate–bicarbonate, pH 9.6) and kept overnight at 4°C. The wells were then incubated with blocking buffer (1% BSA in PBS, pH 7.2) at room temperature for 1 hour and then washed. Diluted serum samples were then added to the microplate, incubated at room temperature for 2 hours, washed and incubated with biotin anti-mouse IgE. This was followed by addition of extravidin-peroxidase at room temperature for 30 min and with 3,3′, 5, 5′-tetramethyl-benzidine substrate for 30 min. The enzymatic reaction was stopped using 2 M H2SO4, and the absorbance was read at 450 nm. Concentrations were determined in duplicates for each sample.
Analysis of bronchoalveolar lavage fluid (BALF): The BALF was collected by cannulation in the upper part of the trachea by infusing PBS in three aliquots (0.5, 0.5, 0.5 mL) in a total volume of 1.3 mL. The fluid was centrifuged and the supernatant was stored at -80°C until cytokine assays. The cell pellets were resuspended in PBS for total cell, eosinophil, and neutrophil counts using hemacytometer by staining with the Wright–Giemsa staining method.
Assay of cytokines: The BALF as obtained above was centrifuged and the supernatant was used for cytokine assay. The assays were performed according to the manufacturer's instructions. IL-4, IL-5 and IL-13 levels in BALF were measured using specific mouse IL-4, IL-5 and IL-13 ELISA as per manufacturer’s instructions.
Measurements of AHR: AHR was assessed as a change in airway function following challenge with aerosolized methacholine via the airway. The mice were anesthetized after 24 hours of last OVA challenge. Tracheotomy was performed as described by Bao et al. (2007). The internal jugular vein was cannulated and connected to a microsyringe for intravenous administration of methacholine. Lung compliance (Cdyn) and airway resistance (RI) in response to increasing concentrations of methacholine were recorded using a whole-body plethysmograph chamber (Buxco, Sharon, CT, USA) as described previously by Teran et al. (1999). The results are expressed as a percentage of the respective basal values in response to PBS.
Western blot analysis: Lung tissues of the mice were excised after 24 hours of last OVA challenge. The tissues were homogenized in liquid nitrogen and incubated in lysis buffer with protease and phosphatase inhibitors (Roche, Basel, Switzerland) to obtain extracts of lung protein. The samples were loaded on to 10% SDS-PAGE gels and were transferred to a polyvinylidene difluo-ride (PVDF) membrane. Following blotting, the blots were exposed to and incubated with specific antibodies against JNK, p38, ERK, p-ERK, p-JNK, p-p38, p-NF-κB p65 and p-IκB in 5% bovine serum albumin (BSA). Membrane was then washed thrice for 5 min each with TBST (Tris-buffered saline and Tween-20). The primary antibody was probed with HRP-conjugated goat anti-rabbit (1:7000) and HRP-conjugated goat anti mouse (1:7000) for 1 hour and washed three times in TBST. Protein bands were visualized using the ECL assay kit (Beyotime, Nantong, China). The band density was normalized to the expression of β-actin.
Statistical analysis: Obtained results are represented as mean ± SD. Values at p<0.05 are considered significant as determined by one-way analysis of variance (ANOVA). The values were analysed using SPSS software (version 17.0).
Th2-type cytokines play a central role in the pathogenesis of allergic asthma by regulating immunoglobulin E (IgE) production. Markedly (p<0.05) raised levels of serum IgE were found in OVA–induced mice as compared against control mice. B. rapa extract at various concentrations (125-500 mg) effectively reduced IgE levels in a dose dependent manner (Figure 1).
Figure 1: Effect of Brassica rapa extract on OVA- specific IgE levels in serum. Values are represented as mean ± SD; n=6; arepresents p<0.05 compared with control as determined by one-way ANOVA
BALF collected 24 hours following OVA challenge in OVA-sensitized mice resulted in marked infiltration of inflammatory cells. Significantly increased levels of the total number of cells, neutrophil and eosinophil counts were recorded in BALF of OVA alone induced mice compared to control group (Figure 2). However, the inflammatory cell counts in BALF of B. rapa extract treated mice were significantly lower as against OVA-challenged mice. B. rapa extract at 500 mg dose was more effective in reducing the cell counts when compared to lower doses of 125 and 250 mg, DEX (2 mg/kg) treatment also significantly inhibited the OVA-induced inflammatory infiltration.
Figure 2: Effect of Brassica rapa extract on cell accumulation in BALF. Brassica rapa extract suppressed the total cell counts (A), eosinophils (B) and neutrophils (C) in BALF; Values are represented as mean ± SD; n=6; arepresents p<0.05 compared with control as determined by one-way ANOVA
Over-expression of Th2-mediated cytokines including IL-4, IL-5, and IL-13 are generally observed in asthma. We used ELISA to determine if B. rapa extract (125,250 or 500 mg/kg) treatment could affect cytokine secretion in the BALF. OVA challenge led to significant increases in the levels of IL-4, IL-5 and IL-13 in BALF, compared with control. In B. rapa extract treatment, 250 and 500 mg/kg doses were effective in suppressing the levels of cytokines in relation to the OVA-challenged group (Figure 3). The same at 500 mg/kg dose reduced interleukin levels similar to DEX.
Figure 3: Effect of Brassica rapa extract on Th2 cytokine levels. Values are represented as mean ± SD; n=6; arepresents p<0.05 compared with control as determined by one-way ANOVA
Asthma is characterized by a non-specific AHR and is defined as excessive narrowing of airways in response to a variety of contractile agonists including OVA. Airway hyperresponsiveness was assessed by measuring Cdyn and RI in response to increasing doses of methacholine administration in mechanically ventilated mice. Cdyn refers to the distensibility of the lung and is defined as the change in volume of the lung produced by a change in pressure across the lung. RI is defined as the pressure driving respiration divided by flow. OVA-challenged mice developed AHR, typically reflected by high RI and low Cdyn (Figure 4). Treatment with B. rapa extract reduced RI and restored Cdyn in OVA-challenged mice in response to methacholine.
Figure 4: Effect of Brassica rapa extract on AHR. Values are represented as mean ± SD; n=6; arepresents p<0.05 compared with control as determined by one-way ANOVA
Asthma development is associated with NF-κB activation that leads to airway inflammation. The MAPK pathway has been reported to play a major role in biological responses, including cytokine expression. The effect of B. rapa extract on MAPK and NF-κB activation was investigated. The lung tissues were collected 24 hours after the final airway OVA challenge, and total and nuclear proteins were extracted. The expression of phosphorylated ERK, JNK, p38, IκB-α and nuclear p-NF-κB p65 and ERK, JNK, p38 in mouse lung tissues are shown in Figure 5 and Figure 6. B. rapa extract suppressed phosphorylation of IκB-α in lung parenchyma, and attenuated nuclear localization of p-NF-κB p65. Furthermore, treatment with B. rapa extract inhibited the phosphorylation level of ERK and p38 signal pathways, but up-regulated phosphorylation of JNK. We found that B. rapa extract at 500 mg/kg blocked ERK phosphorylation and p38 more effectively than lower doses (Figure 5 and 6).
Figure 5: Influence of Brassica rapa extract on the expression of ERK and JNK signalling proteins. (A) Brassica rapa extract modulated expressions of ERK and JNK proteins (B) Relative expression values are represented as mean ± SD; n=6; arepresents p<0.05 compared with control as determined by one way-ANOVA
Figure 6: Brassica rapa extract modulated expressions of p38, IκB-α and nuclear p-NF-κB p65
The early airway response in asthma is IgE dependent and caused by the activation and degranulation of pulmonary mast cells by allergen mediated cross-linking of IgE antibodies bound to the high affinity IgE receptor (FcεRI). Th2 cytokines, including IL-4, IL -5, and IL-13, have been demonstrated to play an important role in the pathogenesis of airway inflammation and responsiveness in animal models and human (Wills-Karp, 1999; Busse and Lemanske, 2001). Th2 responses are triggered by allergen exposure in the airway via activating inflammatory cells and up-regulating IL-4, IL-5 and IL-13 expressions (Bisset and Schmid-Grendelmeier, 2005), which in turn lead to and/or related to airway infiltration, eosinophil activation, IgE production and mucus secretion and AHR as well (Grunig et al., 1998; Larcheet al., 2002; Ngoc et al. 2005; Desai and Brightling, 2012). OVA-induction resulted in a marked raise in airway infiltration of inflammatory cells that was efficiently reduced by B. rapa extract.
In various allergic disorders as asthma, IL-4, IL-5 and IL-13 production levels have been reported to be raise markedly (Busse, 1995; Cohn et al., 1998). The observed results are in line to the previous studies. The raised IL levels following OVA- challenges were significantly reduced by B. rapa extract.
Additionally, IL-4 has been demonstrated to stimulate isotype switching in B cells causing the switch from IgG to IgE production (Fish et al., 2005). IL-5 has been reported to be essential for eosinophils activation and survival, and in development of AHR (Kips et al., 2001). Since IgE levels are dependent on IL-4 and IL-5 and is considered as an additional index of Th2 cytokine secretion in the pathogenesis of asthma, we measured the IgE levels. IgE has also been a key target in developing antiasthma strategies and clinical trials involving the neutralization of IgE have demonstrated satisfactory results in treating asthmatics (Busse and Lemanske, 2001; Hendeles and Sorkness, 2007). In our study, B. rapa extract effectively suppressed IgE levels; this could be due to the direct effect of B. rapa extract or via suppression of ILs. Therefore, the reduction of IgE and Th2 cytokines may account for the improvement in OVA-induced asthma.
AHR is a clinical hallmark of asthma, which is defined as the abnormal increase in airflow limitation in response to stimulus. During allergic inflammation, the development of AHR was associated with inflammatory mediators (Berend et al., 2008). Our data suggested that B. rapa extract was able to effectively attenuate OVA-induced AHR which may be possibly related to suppression of IL-5 (Gleich, 2000).
NF-κB is a critical transcription factor for Th2 cell differentiation (Das et al., 2001; Siebenlist et al., 2005). NF-κB as a central regulator of both innate and adaptive immune responses exerts its function via the induction of genes that promote inflammation, leukocyte migration and activation. Studies have demonstrated that NF-κB activation modulates allergic inflammation responses (Alcorn et al., 2010). In unstimulated cells, however, NF-κB is sequestered in the cytoplasm by IκB inhibitory proteins (Juneja and Parmar, 2013) on activation, NF-κB unit p65 dissociates from the cytoplasm to the nucleus, leading to the synthesis and release of proinflammatory cytokines (Akira et al., 2001; Boulanger et al, 2003).
NF-κB activation has been reported to occur rapidly in the OVA-induced pulmonary inflammation model (Poynter et al., 2002). In our study, we demonstrated that OVA induced p-NF-κB p65 activation and translocation from the cytoplasm to the nucleus was strongly inhibited by B. rapa extract treatment. The phosphorylation of IκBα, were regulated in B. rapa extract treated mice.
Recent studies have reported a raised p38 MAPK and ERK activity in the lungs of asthmatic mice (Kumar et al., 2003). In OVA-sensitized and exposed animal models, a p38 MAPK inhibitor effectively suppressed eosinophilic inflammation in the lungs (Underwood et al., 2000). JNK activity has been shown to be associated with IgE switching (Jabara and Geha, 2005). Therefore, MAPK is a key mediator of allergic diseases. Thus, blockade of p38 MAPK has been shown to have an anti-inflammatory effect in allergic asthma, suggesting that the inhibition and/or regulation of p38 MAPK could possibly be essential for minimizing asthmatic symptoms (Duan et al., 2005). Our results showed that B. rapa extract effectively regulated the activation of p38 and ERK, but had negligible effect on JNK. This suggests that the inhibition of p38 and ERK may have potential benefit in the therapy of asthma.
To summarise B. rapa extract inhibited the activation of NF-κB and MAPK, and reduced inflammatory cytokine and chemokine levels. These findings support a novel therapeutic use of B. rapa extract in the treatment of asthma.
B. rapa extract effectively improves AHR, inhibits Th2 cytokines and inflammatory cell infiltration. B. rapa extract also suppresses p38 MAPK and subsequently disrupts NF-κB activity. Thus by potentially reversing the features of asthma, B. rapa has proven to be a novel candidate in asthma treatment.
Akira S, Takeda K, Kaisho T. Toll-like receptors: Critical proteins linking innate and acquired immunity. Nat Immunol. 2001; 2: 675-680.
Alcorn JF, Ckless K, Brown AL, Guala AS, Kolls JK, Poynter ME, Irvin CG, van der Vliet A, Janssen-Heininger YM. Strain dependent activation of NF-kappaB in the airway epithelium and its role in allergic airway inflammation. Am J Physiol Lung Cell Mol Physiol. 2010; 298: L57-66.
Bao Z, Lim S, Liao W, Lin Y, Thiemermann C, Leung BP, Wong WS. Glycogen synthase kinase-3 beta inhibition attenuates asthma in mice. Am J Respir Crit Care Med. 2007; 176: 431-438.
Berend N, Salome CM, King GG. Mechanisms of airway hyperresponsiveness in asthma. Respirology 2008; 13: 624-631.
Bisset LR, Schmid-Grendelmeier P. Chemokines and their receptors in the pathogenesis of allergic asthma: Progress and perspective. Curr Opin Pulm Med. 2005; 11: 35-42.
Boulanger D, Bureau F, Melotte D, Mainil J, Lekeux P. Increased nuclear factor kappaB activity in milk cells of mastitis-affected cows. J Dairy Sci. 2003; 86: 1259-67.
Busse WW, Lemanske Jr RF. Asthma. N Engl J Med. 2001; 344: 350-62.
Busse WW, Coffman RL, Gelfand EW, Kay AB, Rosenwasser LJ. Mechanisms of persistent airway inflammation in asthma: A role for T cells and T-cell products. Am J Respir Crit Care Med. 1995; 152: 388-93.
Chang L, Karin M. Mammalian MAP kinase signaling cas-cades. Nature 2001; 410: 37.
Chio YH, Park HY. Anti-inflammatory effects of spermidine in lipopolysaccharide stimulated BV2 microglial cells. J Biomed Sci. 2012; 19: 31.
Choi IW, Kim DK, Ko HM, Lee HK. Administration of antisense phosphorothioate oligonucleotide to the p65 subunit of NF-κB inhibits established asthmatic reaction in mice. Int Immunopharmacol. 2004; 4: 1817-28.
Cohn L, Tepper JS, Bottomly K. IL-4-independent induction of airway hyperresponsiveness by Th2, but not Th1, cells. J Immunol. 1998; 161: 3813-16.
Das J, Chen CH, Yang L, Cohn L, Ray P, Ray A. A critical role for NF-κB in GATA3 expression and Th2 differentiation in allergic airway inflammation. Nat Immunol. 2001; 2: 45-50.
Desai D, Brightling C. Cytokines and cytokine-specific therapy in asthma. Adv Clin Chem. 2012; 57: 57-97.
Duan W, Chan JH, McKay K, Crosby JR, Choo HH, Leung BP, Karras JG, Wong WS. Inhaled p38 alpha mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice. Am J Respir Crit Care Med. 2005; 171: 571-78.
Elias JA, Lee CG, Zheng T, Ma B, Homer RJ, Zhu Z. New insights into the pathogenesis of asthma. J Clin Invest. 2003; 111: 291-97.
Fish SC, Donaldson DD, Goldman SJ, Williams CM, Kasaian MT. IgE generation and mast cell effector function in mice deficient in IL-4 and IL-13. J Immunol 2005; 174: 7716-7724.
Gleich GJ. Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol. 2000; 105: 651-63.
Griswold DE, Young PR. Pharmacology of cytokine suppressive anti-inflammatory drug binding protein (CSBP), a novel stress-induced kinase. Pharmacol Commun. 1996; 7: 323-29.
Grunig G, Warnock M, Wakil AE, Venkayya R, Brombacher F, Rennick DM, Sheppard D, Mohrs M, Donaldson DD, Locksley RM, Corry DB. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 1998; 282: 2261-63.
Hendeles L, Soreness CA. Anti-immunoglobulin E therapy with omalizumab for asthma. Ann Pharmacother. 2007; 41: 1397-410.
Herrick CA, Bottomly K. To respond or not to respond: T cells in allergic asthma. Nat Rev Immunol. 2003; 3: 1.
Hocaoglu AB, Karaman O, Erge DO, Erbil G, Yilmaz O, Bagriyanik A, Uzuner N. Glycyrrhizin and long-term histopathologic changes in a murine model of asthma. Curr Thera Res. 2011; 72: 250-61.
Jabara HH, Geha RS. Jun N-terminal kinase is essential for CD40-mediated IgE class switching in B cells. J Allergy Clin Immunol. 2005; 115: 856-63.
Janson C. The importance of airway remodeling in the natural course of asthma. Clin Respir J. 2010; 4: 28-34.
Juneja L, Parmar HS. Ovalbumin induced allergic rhinitis and development of prediabetes to rats: possible role of Th2 cytokines. Inflamm Allergy Drug Targets. 2013; 12: 199-205.
Kang NI, Yoon HY, Lee YR, Won M, Chung MJ, Park JW, Hur GM, Lee HK, Park BH. A20 attenuates allergic airway inflammation in mice. J Immunol. 2009; 183: 1488-95.
Kips JC, Tournoy KG, Pauwels RA. New antiasthma therapies: Suppression of the effect of interleukin (IL)-4 and IL-5. Eur Respir J. 2001; 17: 499-506.
Kumar A, Lnu S, Malya R, Barron D, Moore J, Corry DB, Boriek AM. Mechanical stretch activates nuclear factor-kappaB, activator protein-1, and mitogen-activated protein kinases in lung parenchyma: implications in asthma. FASEB J. 2003; 17: 1800.
Larche M, Robinson DS, Kay AB. The role of T lymphocytes in the pathogenesis of asthma. J Allergy Clin Immunol. 2002; 111: 450-63.
Leigh R, Ellis R, Wattie JN, Hirota JA, Matthaei KI, Foster PS, O'Byrne PM, Inman MD. Type 2 cytokines in the pathogenesis of sustained airway dysfunction and airway remodeling in mice. Am J Respir Crit Care Med. 2004; 169: 860-67.
Li XM, Brown L. Efficacy and mechanisms of action of Traditional Chinese Medicines for treating asthma and allergy. J Allergy Clin Immunol. 2009; 123: 297-308.
Li XM. Complementary and alternative medicine in pediatric allergic disorders. Curr Opin Allergy Clin Immunol. 2009; 9: 161-67.
Li X M. Treatment of asthma and food allergy with herbal interventions from Traditional Chinese Medicine. Mt Sinai J Med. 2011; 78: 697-716.
Ngoc PL, Gold DR, Tzianabos AO, Weiss ST, Celedon JC. Cytokines, allergy, and asthma. Curr Opin Allergy Clin Immunol. 2005; 5: 161-66.
Oh SW, Pae CI, Lee DK, Jones F, Chiang GK, Kim HO, Moon SH, Cao B, Ogbu C, Jeong KW, Kozu G, Nakanishi H, Kahn M, Chi EY, Henderson Jr WR. Tryptase inhibition blocks airway inflammation in a mouse asthma model. J Immunol. 2002; 168: 1992-2000.
Podsedek A. Natural antioxidants and antioxidant capacity of Brassica vegetables: A review. LWT-Food Sci Technol. 2007; 40: 1-11.
Powers SK, DeRuisseau KC, Quindry J, Hamilton KL. Dietary antioxidants and exercice. J Sports Sci. 2004; 22: 81-94.
Poynter ME, Irvin CG, Janssen-Heininger YM. Rapid activation of nuclear factor-kappaB in airway epithelium in a murine model of allergic airway inflammation. Am J Pathol. 2002; 160: 1325-34.
Shahzad M, Yang X, Raza Asim MB, Sun Q, Han Y, Zhang F, Cao Y, Lu S. Black seed oil ameliorates allergic airway inflammation by inhibiting T-cell proliferation in rats. Pulmonary Pharmacol Ther. 2009; 22: 37-43.
Siebenlist U, Brown K, Claudio E. Control of lymphocyte development by NFkB. Nat Rev Immunol. 2005; 5: 435-45.
Teran LM, Mochizuki M, Bartels J, Valencia EL, Nakajima T, Hirai K, Schroder JM. Th1- and Th2-type cytokines regulate the expression and production of eotaxin and RANTES by human lung fibroblasts. Am J Respir Cell Mol Biol. 1999; 20: 1044-49.
Underwood DC, Osborn RR, Kotzer CJ, Adams JL, Lee JC, Webb EF, Carpenter DC, Bochnowicz S, Thomas HC, Hay DW, Griswold DE. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. J Pharmacol Exp Ther. 2000; 293: 281-88.
Walsh GM. Novel therapies for asthma: Advances and problems. Curr Pharmaceut Design. 2005; 11: 3027-38.
Wills-Karp M. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu Rev Immunol. 1999; 17: 255-81.
Wu X, Beecher GR, Holden J, Haytowitz DB, Gebhardt SE, Prior RL. Lipophylic and hidrophylic antioxidant capacities of common foods in United States. J Agric Food Chem. 2004, 52: 4026-37.